IMPACT THERAP-B (07630.HK): Interim revenue up 316.8% to RMB 105.2 million as Senaparib sales ramp up, loss narrows 29.5%

NewTimeSpace News: On 14 September 2026, IMPACT Therapeutics, Inc (stock code: 07630) published its 2026 interim report, announcing unaudited results for the six months ended 30 June 2026. Revenue for the period was RMB 105.2 million, up 316.8% from RMB 25.2 million a year earlier, comprising pharmaceutical sales of RMB 70.4 million, or 66.9% of total revenue, and licensing income of RMB 34.8 million, or 33.1%; gross profit was RMB 95.5 million, representing a gross margin of 90.8%.

Senaparib (IMP4297), a PARP1/2 inhibitor and the Company's core product, has been included in the National Reimbursement Drug List for first-line maintenance treatment of ovarian cancer across the all-comers population with effect from 1 January 2026, which drove rapid expansion of market coverage. Revenue from Senaparib sales in China for the six months ended 30 June 2026 was RMB 70.4 million, an increase of approximately RMB 63.2 million, or 877.8%, from RMB 7.2 million a year earlier; as at 30 June 2026, Senaparib covered all provinces in the Chinese mainland, was available in more than 380 specialty and community pharmacies and reached nearly 1,200 medical institutions. In July 2026, the Company entered into an exclusive collaboration with Pharmanovia, granting it exclusive rights to manufacture, develop and commercialise Senaparib in Europe, the Middle East and North Africa, Australia and New Zealand, under which the Company is eligible to receive payments of up to EUR 423.5 million together with tiered royalties on net sales, extending Senaparib's global coverage to 66 countries.

On research and development, the Company's R&D expenses for the period were RMB 97.6 million, up 13.1% year on year, mainly due to higher expenses relating to the European Medicines Agency's review of the marketing authorisation application for Senaparib and increased preclinical R&D activities for early-stage candidates; administrative expenses rose approximately 72.3% to RMB 50.3 million mainly due to higher listing expenses; and selling and distribution expenses rose to RMB 22.8 million on expanded market coverage and higher CSO service fees. Loss for the period was RMB 90.8 million, narrowing 29.5% from RMB 128.7 million a year earlier; adjusted net loss was RMB 20.9 million, narrowing 62.6% from RMB 55.8 million; and basic and diluted loss per share was RMB 0.37 (same period in 2025: RMB 0.58).

Financially, as at 30 June 2026, the Company's cash and cash equivalents, time deposits and financial assets at fair value through profit or loss totalled RMB 1,065.4 million, up 312.1% from RMB 258.5 million as at 31 December 2025, mainly due to the global offering proceeds received in May 2026 and cash generated from Senaparib sales, while net assets turned positive at RMB 775.8 million against net liabilities of RMB 957.9 million as at 31 December 2025. The Company listed on the Stock Exchange on 13 May 2026, issuing 41,977,000 H shares at HKD 20.10 per share, followed by a further 6,296,400 H shares on 10 June 2026 upon full exercise of the over-allotment option, with net proceeds from the global offering, after deducting underwriting commissions and related costs and expenses, of approximately HKD 879 million. The Board has resolved not to recommend the payment of an interim dividend for the six months ended 30 June 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.